EIC Accelerator eligibility: TRL 5, funding options and what evaluators look for

Start with eligibility, not the application form

The EIC Accelerator supports single startups and SMEs developing game-changing innovations with the potential to create or disrupt markets. The company must normally be established in an EU Member State or a country associated with Horizon Europe; specific routes also exist for natural persons or entities intending to establish an eligible company, while small mid-caps may apply for investment only.

But legal eligibility is only the first gate. The programme is designed for high-risk innovations that need substantial finance and cannot yet be fully financed by private investors alone. Your proposal therefore needs to show both exceptional upside and a credible reason why EIC support is needed now.

A useful distinction: previous public funding, private investment and investor interest are not universal eligibility conditions. They can, however, provide strong evidence of traction, external validation and your ability to attract the co-financing required for growth.

The critical technology threshold: completed TRL 5

For the 2026 EIC Accelerator, applicants must demonstrate that the innovation has completed all aspects of Technology Readiness Level 5. The grant-funded development then covers innovation activities from TRL 6 to TRL 8.

TRL 5 means that the technology has been validated in a relevant environment. This is more demanding than showing that components work in the laboratory. You should have an integrated or sufficiently representative technology configuration and evidence that it performs under conditions that reflect its intended application.

The exact evidence depends on the innovation. For an industrial technology, it may mean validation using representative materials, loads, operating conditions or production constraints. For hardware, it may involve a prototype or subsystem tested in a setting that reproduces the essential conditions of use. For software, it may mean validating a functioning system with representative users, datasets, integrations and performance requirements.

Evaluators will not accept a TRL label on its own. They need traceable evidence: test protocols, results, success criteria, independent validation where relevant, and a clear explanation of why the environment is representative.

What does TRL 5 mean for clinical and health projects?

Health innovation requires a particularly careful interpretation because TRLs do not map neatly onto a single clinical or regulatory milestone. The relevant environment depends on whether you are developing a therapeutic, diagnostic, medical device, digital health product or another technology.

Therapeutics and biotechnology

TRL 5 will usually require robust validation beyond an initial proof of concept: for example, reproducible performance in disease-relevant models, evidence supporting the mechanism of action, and a sufficiently mature formulation, delivery or manufacturing concept. This does not automatically mean that a clinical trial must already have been completed. The appropriate evidence depends on the product, indication and regulatory pathway.

Medical devices, diagnostics and digital health

TRL 5 may involve a functioning prototype validated in a representative clinical, laboratory or simulated-use setting, using representative samples, data, users and workflows. Formal clinical validation or certification may come later, but the evidence should already reduce the central technical risk in the intended application.

Practical point: define the intended use first, then explain why your test environment, model, samples and users are relevant to that use. For health projects, align the TRL argument with the regulatory and clinical development plan rather than treating it as a separate exercise.

What funding can the EIC Accelerator provide?

The instrument can combine grant support for innovation activities with patient investment capital for market deployment and scale-up.

Grant only

A lump-sum grant below €2.5 million for TRL 6–8 innovation activities. Eligible costs are funded at up to 70%.

Blended finance

The grant component combined with direct equity or quasi-equity, such as convertible instruments.

Investment only

For eligible companies that need capital to scale rapidly but do not need the grant component.

Under the 2026 programme, the standard investment component can reach €10 million. The appropriate amount and structure are assessed during due diligence. Because the grant covers a maximum of 70% of eligible costs, the company must plan how it will cover the balance.

Choosing between grant only, blended finance and investment only should follow the financing logic of the company. The funding request must connect clearly to the technical roadmap, commercial milestones, cash needs and the risks that private capital is not yet prepared to carry.

What evaluators are really looking for

Eligibility gets you through the door. A competitive application must then make a coherent case across excellence, impact and implementation. In practice, evaluators need to see:

• A genuinely breakthrough innovation. The technology should offer a meaningful advantage over alternatives and have the potential to create or transform a market.
• Convincing technical evidence. Your TRL 5 claim should be supported by results, not aspirations, with the remaining risks made explicit.
• A defensible position. Strong intellectual property, freedom to operate and a credible IP strategy should protect the route to market.
• A clear market opportunity. TAM, SAM and SOM must be evidence-based and connected to identifiable customers, competitors, adoption drivers and pricing assumptions.
• A credible route to market. Explain whether you will sell directly, partner, license or pursue another model, and show the milestones that lead to commercialisation.
• A realistic implementation plan. Work packages, deliverables, milestones, resources, dependencies and risks should form one credible path from TRL 5 towards market readiness.
• The right team. The core team and advisory board should cover the scientific, technical, regulatory, commercial and scale-up capabilities the plan requires.
• Transparent financials. Forecasts, funding needs and assumptions must be consistent with the work plan and growth strategy.
• Scale and impact. Show how the project can deliver substantial market, societal, environmental or strategic value for Europe.

A quick EIC Accelerator readiness checklist

• You are an eligible startup or SME, or have a valid route to establish one.
• Your innovation has completed every relevant aspect of TRL 5.
• Your test evidence reflects the intended application environment.
• The innovation is breakthrough, defensible and able to create or disrupt a market.
• You can explain why private finance alone will not cover the current risk.
• Your work plan connects technical, regulatory and commercial milestones.
• Your market model, financial assumptions and funding request are consistent.
• Your team can execute the development and scale-up plan.

If several of these points remain uncertain, the right first step may be a readiness assessment rather than immediately drafting the proposal. A clear no—or not yet—can save months of work and help you build the evidence for a stronger future application.

Official sources

European Commission — EIC Accelerator
European Commission — EIC Work Programme 2026
European Commission — Technology readiness levels

This article provides general guidance. Always check the current Work Programme and call documents before applying.